- Language: English
- 1007 Pages
- Published: March 2013
- Region: Global
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
- Published: October 2006
- Region: Global
- 125 Pages
With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic chemotherapy agents.
Scope of this report
- In-depth competitive landscape assessment of the anti-angiogenesis market in oncology
- Thorough review of utilized targets in anti-angiogenic and vascular target drug development
- Thorough review of approved drugs
- Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls
- Research and analysis highlights
Companies with the ten highest numbers of clinical trials make up more than 40% of all research and development done in anti-angiogenesis and vascular targeting in onoclogy, but they just constitute 10% of the competitors in the field.
More than 100 anti-angiogenic drugs have been described with one or more targets. These 75 drug targets are a mixture of weaker and stronger targets in angiogenesis.
The prostate cancer market is reaching maturity, and major players’ sales have been eroded by the launch of various LHRH agonist depot formulations, we identify that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer.
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization of anti-angiogenic and vascular targeting drugs
- Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development
Some of the almost 100 drugs included in this analysis
2-methoxyestradiol, AMG-706, ATN-161, AZD-2171, bevacizumab, combretastatin A-4 prodrug, enzastaurin hydrochloride, everolimus, neovastat, PTK/ZK, sorafenib tosylate, squalamine, thalidomide, vitaxin, XL-999, ZD-6474, volociximab etc. SHOW LESS READ MORE >
1 Executive Summary
2 Cancer Highlights
4 Table of Contents
4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables
5.1 Neoplastic Angiogenesis & Tumor Vasculature
5.1.1 Tumor Vasculature
5.1.2 The Current Model of Sprouting Angiogenesis
5.2 Main Angiogenic Factors
5.2.1 Vascular Endothelial Growth Factor
5.2.2 The Angiopoietins and Platelet Derived Growth Factor
5.2.3 Integrins in Angiogenesis
5.2.4 Inhibitors of Angiogenesis
5.3 Vascular Targeting Agents
5.4 Vascular Disruptive Agents
6 Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology
6.1 Countries & Players: Who are In the Lead?
6.1.1 Top 10 Players Dominate The Developmental Pipeline
6.2 Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
6.2.1 Review of Deals and Alliances Initiated in 2005
6.2.2 Review of Deals and Alliances Initiated in 2004
6.2.3 Review of Deals and Alliances Initiated in 2003
7 Approved Anti-Angiogenic Cancer Drugs: Performance
8 Target Analysis in Anti-Angiogenesis and Vascular Targeting
8.1 Targets of Late Stage Anti-Angiogenic Drugs in Development
8.1.1 Drugs with Epidermal Growth Factor Receptor as a Target
8.1.2 Drugs with FMS-related Tyrosine Kinase 1 as a Target
8.1.3 Drugs with FMS-related Tyrosine Kinase 4 as a Target
8.1.4 Drugs with Kinase Insert Domain Receptor as a Target
8.1.5 Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
8.1.6 Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
8.1.7 Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
8.1.8 Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
8.1.9 Drugs with Protein Kinase C, beta 1 as a Target
8.1.10 Drugs with Ret Proto-Oncogene as a Target
8.1.11 Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a
8.1.12 Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
8.1.13 Drugs with Vascular Endothelial Growth Factor as a Target
8.2 Anti-Angiogenic Drugs and Their Targets According to Top 5 Cancer Indications
8.2.1 Targets in Breast Cancer
8.2.2 Targets in Colorectal Cancer
8.2.3 Targets in Lung Cancer
8.2.4 Targets in Prostate Cancer
8.2.5 Targets in Renal Cancer
9 Anti-angiongenesis and Vascular Targeting Drugs in Development: By Major Indications
9.1 General Drug Developmental Overview
9.2 Progress Analysis – Breast Cancer
9.2.1 Phase I Clinical Development.
9.2.2 Phase II Clinical Development
9.2.3 Phase III Clinical Development
9.3 Progress Analysis – Colorectal Cancer
9.3.1 Phase I Clinical Development
9.3.2 Phase II Clinical Development
9.3.3 Phase III Clinical Development
9.4 Progress Analysis – Lung Cancer
9.4.1 Phase I Clinical Development
9.4.2 Phase II Clinical Development
9.4.3 Phase III Clinical Development
9.5 Progress Analysis – Prostate Cancer
9.5.1 Phase I Clinical Development
9.5.2 Phase II Clinical Development
9.5.3 Phase III Clinical Development
9.6 Progress Analysis – Renal Cancer
9.6.1 Phase I Clinical Development
9.6.2 Phase II Clinical Development
9.6.3 Phase III Clinical Development
11 Appendix I: Complete List of Angiogenic and Vascular Target Agents in Development in Oncology
12 Drug Index
13 Company Index
4.1 List of Boxes
Box 1: Nexavar’s Clinical Data That Lead To Its EMEA Approval Myeloma
Box 2: Thalomid Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
Box 3: Strong Clinical Data Suggests Approval to Market Avastin For The Treatment of Both Breast Cancer and NSCLC
Box 4: Avastin Fails to Meet Primary Endpoint in Advanced Pancreatic Cancer
Box 5: Business & Market – Cilengitide
Box 6: Business & Market – Exherin
Box 7: Business & Market – WX-UK1
Box 8: Business & Market – Combretastatin A-4 phosphate
Box 9: Business & Market – GCS-100LE
Box 10: Business & Market – PTK/ZK
Box 11: Business & Market – AS-1404
Box 12: Business & Market – Phosphomannopentaose sulfate
Box 13: Business & Market – Squalamine
Box 14: Business & Market – talactoferrin alfa
Box 15: Business & Market – ZD-6474
Box 16: Business & Market – AP-23573
Box 17: Business & Market – Volociximab
Box 18: Business & Market – XL-999
4.2 List of Figures
Figure 1: Establishment of Blood Supply to Tumors
Figure 2: Sprouting Angiogenesis
Figure 3: Top 5 Countries in Cancer Angiogenesis and Vascular Targeting Research
Figure 4: Top 10 Companies’ Clinical Trial Progress in Anti-Angiogenesis and Vascular Targeting
Figure 5: Deals & Alliances in Anti-Angiogenesis and Vascular Targeting 2001-2005
Figure 6: Annual Sales of Avastin on US and Non US Markets
Figure 7: Trial Distribution of the Entire Anti-Angiogenic and Vascular Target Agent Field in Oncology
Figure 8: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Breast Cancer
Figure 9: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Colorectal
Figure 10: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Lung Cancer
Figure 11: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Prostate Cancer
Figure 12: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Renal Cancer
4.3 List of Tables
Table 1: Top 10’s Anti-angiogenic and Vascular Targeting Pipeline Drugs
Table 2: Deals & Alliances in 2005
Table 3: Deals & Alliances in 2004
Table 4: Deals & Alliances in 2003
Table 5: Companies with Cancer Anti-angiogenic Drugs on the Market
Table 6: 2006 Q2 Sales Revlimid and Thalomid
Table 7: 2006 Q2 Sales of Avastin
Table 8: List of 75 Known Targets in Ant-angiogenis and Vascular Targeting in Drug Development
Table 9: Known Targets of Late Stage Anti-Angiogenic Drugs in Development
Table 10: Drugs with Epidermal Growth Factor Receptor as a Target
Table 11: Drugs with FMS-related Tyrosine Kinase 1 as a Target
Table 12: Drugs with FMS-related Tyrosine Kinase 4 as a Target
Table 13: Drugs with Kinase Insert Domain Receptor as a Target
Table 14: Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
Table 15: Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
Table 16: Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
Table 17: Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
Table 18: Drugs with Protein Kinase C, beta 1 as a Target
Table 19: Drugs with Ret Proto-Oncogene as a Target
Table 20: Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
Table 21: Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
Table 22: Drugs with Vascular Endothelial Growth Factor as a Target
Table 23: Breast Cancer Targets in Anti-Angiogenic Drug Development
Table 24: Colorectal Cancer Targets in Anti-Angiogenic Drug Development
Table 25: Lung Cancer Targets in Anti-Angiogenic Drug Development
Table 26: Prostate Cancer Targets in Anti-Angiogenic Drug Development
Table 27: Renal Cancer Targets in Anti-Angiogenic Drug Development
Table 28: Top 10 Cancer Indications in Anti-Angiogenesis and Vascular Targeting Cancer Drugs
Table 29: Recent Ceased or Discountinued Phase I to Phase III Anti-angiogenic and Vascular Targeting Drugs
Table 30: Overview of Drugs in Phase III Clinical Development
Table 31: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Breast Cancer
Table 32: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Colorectal Cancer
Table 33: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Lung Cancer
Table 34: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Prostate Cancer
Table 35: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Renal Cancer
- Abbott Laboratories, Inc.
- Active Biotech AB
- Adherex Technologies
- Aeterna Zentaris, Inc
- Affitech AS
- Agennix Inc
- Alchemgen Therapeutics, Inc.
- Ambit Biosciences
- Amgen, Inc.
- Angiogene Pharmaceuticals, Ltd.
- AnorMED, Inc.
- Antisoma plc
- Applied Molecular Evolution, Inc.
- Ariad Pharmaceuticals, Inc.
- Atrium Biotechnologies, Inc.
- Attenuon LLC
- Bayer AG
- BioAlliance Pharma
- BioAxone Therapeutic, Inc
- Biogen IDEC, Inc.
- Biotica Technology, Ltd
- Boehringer Ingelheim GmbH
- Bolder BioTechnology
- Bristol-Myers Squibb
- Cancer Research Technology
- Cancer Research UK
- Celgene Corporation
- Cell Genesys, Inc
- Cell Pathways
- Cell Therapeutics, Inc.
- Cephalon, Inc.
- CGI Pharmaceuticals, Inc.
- Chemokine Therapeutics Corp.
- Chiron Corporation
- Chroma Therapeutics, Ltd
- Chugai Pharmaceutical Co., Ltd.
- Dendreon Corporation
- Eisai Co, Ltd.
- Elan Corporation plc
- Eli Lilly
- Eli Lilly & Company, Ltd.
- EMD Pharmaceuticals
- EntreMed, Inc.
- Exelixis, Inc.
- F Hoffmann-La Roche, Ltd.
- Food and Drug Administration
- Genentech, Inc.
- Genzyme Corporation
- Gilead Sciences, Inc
- GlycoGenesys, Inc.
- Green Cross Corporation
- Idera Pharmaceuticals, Inc.
- Introgen Therapeutics
- Isis Pharmaceuticals, Inc.
- Johnson & Johnson
- KAI Pharmaceuticals
- Kirin Brewery Co, Ltd.
- Kyowa Hakko Kogyo Co, Ltd.
- Locus Pharmaceuticals, Inc.
- Lorus Therapeutics, Inc.
- Ludwig Institute for Cancer Research
- Medarex, Inc.
- Medigen Biotechnology
- MediGene AG
- MedImmune, Inc.
- Merck & Co, Inc.
- Merck KGaA
- Micromet, Inc.
- National Institute of Health
- National Institute of Health (USA)
- Nereus Pharmaceuticals, Inc
- Novartis International AG
- Nowicky Pharma
- Onconova Therapeutics, Inc
- Onyx Pharmaceuticals, Inc.
- OSI Pharmaceuticals, Inc.
- OXiGENE, Inc.
- PDL BioPharma
- Peregrine Pharmaceuticals
- Pfizer, Inc.
- PharmaMar SA
- Pharmion Corporation
- Praecis Pharmaceuticals, Inc
- Protein Design Labs, Inc.
- PTC Therapeutics
- Santaris Pharma A/S
- Schering AG
- Scripps Research Institute
- Semafore Pharmaceuticals, Inc.
- Shire Pharmaceuticals Group plc
- Sigma-Tau, SpA
- Sirna Therapeutics, Inc
- Spear Therapeutics
- Supratek Pharma, Inc
- TargeGen, Inc.
- Thios Pharmaceuticals
- UCB Pharma, Ltd
- Wilex AG
- Wyeth Corp
- Xantos Biomedicine
- Xenova Group plc
- Xerion Pharmaceuticals AG
- 2C3 antibody
- 5F 203
- AAB1 antibodies
- anti-NP-1 MAbs
- AZD 6474
- BAY 439006
- BAY 43-9006
- CA4 phosphate
- CGP 79787
- Combretastatin A4 Prodrug
- DCGP 79787
- Dehydrodidemnin B
- Del-1 MAb
- Didemnin B
- GFKI 258
- MEDI 522
- MX-2105 series
- Mycobacterial cell wall-DNA complex
- N-cadherin antagonists
- OB-cadherin antibodies
- Phosphomannopentaose sulfate
- PTK 787
- Sulindac sulfone
- VE-cadherin antibodies
- ZK 222584